Boston Scientific Corporation (NYSE: BSX) has announced its financial results for the fourth quarter and full year of 2025. The company reported net sales of $5.286 billion during the fourth quarter, marking a 15.9 percent growth on a reported basis, 14.3 percent on an operational basis, and 12.7 percent on an organic basis compared to the prior year period. This growth is significant, showcasing the company's ability to deliver strong performance.
For the full year 2025, Boston Scientific generated net sales of $20.074 billion, reflecting a 19.9 percent growth on a reported basis, 19.2 percent on an operational basis, and 15.8 percent on an organic basis compared to the prior year period. This demonstrates sustained growth throughout the year.
The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share for the fourth quarter, compared to $566 million or $0.38 per share a year ago. Additionally, it achieved adjusted EPS of $0.80 for the period, compared to $0.70 a year ago. For the full year 2025, Boston Scientific reported GAAP net income attributable to common stockholders of $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share a year ago, and delivered full year adjusted EPS of $3.06, compared to $2.51 a year ago.
In terms of segment and regional performance, the company achieved net sales growth across its reportable segments and regions. For example, in the medsurg segment, there was an 11.7 percent reported, 10.2 percent operational, and 6.5 percent organic growth compared to the prior year period. In the United States, net sales grew by 17.0 percent on both reported and operational bases.
Looking ahead, Boston Scientific provided guidance for the full year and first quarter of 2026. The company estimates net sales growth for the full year 2026 to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis. For the first quarter of 2026, net sales growth is estimated to be approximately 10.5 to 12.0 percent on a reported basis and 8.5 to 10.0 percent on an organic basis.
These figures reflect Boston Scientific's strong performance in 2025 and its optimistic outlook for the year ahead. With a focus on innovative medical technologies and a track record of growth, the company is poised to continue its growth trajectory in the future. The market has reacted to these announcements by moving the company's shares -2.18% to a price of $88.07. Check out the company's full 8-K submission here.
